ALPINE: Maintenance Letrozole/Abemaciclib
NCT06366347
This study is recruiting at 6 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53) wild-type endometrial cancer. The names of the study drugs involved in this study are: Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor) Letrozole (a type of aromatase inhibitor)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Endometrial Cancer
- Recurrent Endometrial Cancer
- TP53
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Dana-Farber Cancer Institute
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado Cancer Center · Aurora, CO
Massachusetts · 4
- Beth Israel Deaconess Medical Center · Boston, MA
- Brigham and Women's Hospital · Boston, MA
- Dana-Farber Cancer Institute · Boston, MA
- Dana-Farber Cancer Institute at South Shore Hospital · Weymouth, MA
Oklahoma · 1
- OU Health Stephenson Cancer Center · Oklahoma City, OK
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.